A Pivotal Phase 3 Clinical Trial to Assess the Diagnostic Performance and Safety of [68Ga]Ga-PentixaFor ([68Ga]Ga-PTF), a Positron Emission Tomography (PET) Imaging Agent, Versus [18F]FDG PET/CT Imaging, for Staging of Patients With Confirmed Marginal Zone Lymphoma Exemplary for CXCR4-positive Malignant Lymphomas: a Prospective, International, Multi-center, Comparative, Randomized, Cross-over, Open-label Lymphoma Diagnostic Trial
Latest Information Update: 16 Jun 2025
At a glance
- Drugs 68Ga PentixaFor (Primary) ; Fludeoxyglucose F-18
- Indications Lymphoma
- Focus Diagnostic use
- Acronyms LYMFOR
- Sponsors PentixaPharm
Most Recent Events
- 10 Jun 2025 Status changed from recruiting to active, no longer recruiting.
- 03 Jun 2024 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 May 2024 to 1 Jun 2024.
- 03 Jun 2024 Status changed from not yet recruiting to recruiting.